The FDA approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism following hip or knee replacements and for the prevention of stroke in patients with nonvalvular atrial fibrillation.
Ogechukwu Okonkwo, PharmD Candidate
Advertisement
Articles by Ogechukwu Okonkwo, PharmD Candidate
Advertisement
Latest Updated Articles
- Janssen Pharmaceuticals' Xarelto
Published: December 7th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why
2
Pharmacy Policy Updates for October 2025
3
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
4
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
5
